Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBCC 2024 | Elucidating the role of radiotherapy in treating brain metastases in breast cancer

Orit Kaidar-Person • 21 Mar 2024
EBCC 2024
Breast Cancer

Patients with breast cancer and brain metastases are typically heavily pretreated and suffer from cognitive dysfunction. Clinicians must also take into account the heterogenous nature of brain metastases when treating them. Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel, comments on the potential benefits of radiotherapy for brain metastases in breast cancer. Radiation can preserve cognitive function in patients and certain forms of radiotherapy such as stereotactic radiotherapy can preserve hippocampal function. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Orit Kaidar-Person

The role of regional node irradiation for low-burden breast cancer
0:53
The role of regional node irradiation for low-burden breast cancer
Orit Kaidar-Person • 13 Mar 2025
Do all low-burden breast cancer cases need regional node irradiation?
0:50
Do all low-burden breast cancer cases need regional node irradiation?
Orit Kaidar-Person • 13 Mar 2025
Indicating radiotherapy after breast-conserving therapy & mastectomy
1:28
Indicating radiotherapy after breast-conserving therapy & mastectomy
Orit Kaidar-Person • 13 Mar 2025
Unanswered questions in early breast cancer care at St Gallen 2025
0:40
Unanswered questions in early breast cancer care at St Gallen 2025
Orit Kaidar-Person • 13 Mar 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals